Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Mehr anzeigen
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology...
GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.64 | -7.70156438026 | 8.31 | 8.75 | 7.3746 | 2824153 | 7.99362093 | CS |
| 4 | -1.12 | -12.7417519909 | 8.79 | 10.88 | 7.3746 | 3408424 | 8.81666917 | CS |
| 12 | 1.42 | 22.72 | 6.25 | 11.16 | 5.92 | 3129695 | 8.22242446 | CS |
| 26 | 1.34 | 21.1690363349 | 6.33 | 11.16 | 5.275 | 2845960 | 7.52800154 | CS |
| 52 | -3.88 | -33.5930735931 | 11.55 | 14.84 | 5.275 | 3901032 | 8.78851852 | CS |
| 156 | -1.47 | -16.0831509847 | 9.14 | 23.49 | 2.09 | 2921878 | 8.12067395 | CS |
| 260 | 5.91 | 335.795454545 | 1.76 | 35.1 | 1.6 | 2521450 | 9.70424215 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
